Ocular Therapeutix randomizes more than 300 patients in SOL-1 Phase 3 trial for OTX-TKI

News
Article

The trial is expected to close randomization in early December 2024.

Doctor showing patient a tablet Image credit: AdobeStock/bongkarn

Image credit: AdobeStock/bongkarn

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This is the first registrational clinical trial of OTX-TKI in wet age-related macular degeneration (wet AMD) and is on track to report topline data in the fourth quarter of 2025.1

Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix shared his thoughts on this milestone in the company’s press release1, saying, “SOL-1 reaching target randomization in 2024 is a landmark event for Ocular. SOL-1 is an important trial for patients and the retina community as there is an urgent unmet need for durable therapies capable of maintaining visual acuity and improving long-term outcomes. Today’s milestone brings us one step closer to our goal of delivering the first wet AMD therapy potentially capable of being dosed as infrequently as every six to nine months. Achieving this progress reflects our positive engagement with the retina community, the dedication of our clinical sites, and the demand for a durable treatment option for wet AMD.”

Dugel continued, “Thanks to the excellent momentum from SOL-1, we recently ‘flipped the switch’, allowing active clinical sites to enroll patients directly into our second registrational study in wet AMD, SOL-R, further accelerating its pace of enrollment. Thanks to the palpable enthusiasm from the investigators and study site teams, we continue to make excellent progress with the enrollment of SOL-R, with a steady focus on our overall mission of improving vision for patients.”1

The momentum of SOL-1 has benefitted Ocular’s second registrational clinical trial, the SOL-R repeat dosing trial. Earlier in Q4 of 2024, Ocular allowed investigators to enroll their patients directly into SOL-R. Previously, patients were required to be a SOL-1 loading or randomization failure. The SOL-R trial has seen an acceleration in recruitment and expected to be amplified by subjects enrolled but not ultimately randomized into SOL-1 because randomization targets are met. Ocular continues to activate additional clinical trial sites worldwide to further the speed of SOL-R enrollment.1

About the SOL-1 and SOL-R studies

Ocular’s wet AMD registrational program for OTX-TKI is comprised of 2 complementary studies, designed with the intent of de-risking clinical outcomes, aligning with regulatory standards, enhancing each other’s enrollment, and providing a broad evaluation of durability, repeatability, and flexibility. SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA). In a written Type C response, the FDA agreed that the SOL-R non-inferiority study should be appropriate as a second adequate and well-controlled study to support a potential New Drug Application (NDA).1

Reference:
  1. Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1. Ocular Therapeutix, Inc. December 2, 2024. December 3, 2024. https://www.globenewswire.com/news-release/2024/12/02/2989687/0/en/Ocular-Therapeutix-Announces-More-Than-300-Subjects-Randomized-in-SOL-1.html

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
© 2025 MJH Life Sciences

All rights reserved.